Moderna's study combines with Merck's Keytruda, and Jim Cramer advises investors on Moderna's stock.
5 reports, 3 independent
Updated Oct 15
Gone quiet
- Reports
- 5
- Developments
- 1
- Repetition
- 80%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Moderna's study combines with Merck's Keytruda, and Jim Cramer advises investors on Moderna's stock.
Who's involved
What this event is mainly aboutKeep exploring
Part of
Moderna and Merck personalized cancer vaccine advancementAlso in this story
- Moderna and Merck KGaA are working on personalized melanoma shots, with manufacturing challenges being discussed by Amy Walker.
- Moderna and Merck announced a landmark moment in vaccine testing, alongside updates regarding personnel at Moderna and Columbia University.
- Moderna combined its vaccine with Merck's Keytruda drug.
- Moderna, Merck, and Georgetown Lombardi Comprehensive Cancer Center are collaborating on developing a personalized cancer vaccine combination.
The entities involved
Related events
- Moderna's stock gains are being driven by FDA approval and the broader growth of AI businesses, as a Nasdaq constituent.
- Moderna, Pfizer, and Merck are part of a healthcare rotation story, with Moderna outperforming Pfizer in current stock gains.
- Multiple financial firms acquired, increased, or lessened stakes in Moderna shares, while the company president also sold shares.